Clinical efficacy and safety of moxifoxacin versus levofoxacin plus metronidazole for community-acquired pneumonia with aspiration factors

Chinese Medical Journal

Volumn 127, Issue 7, 2014, Pages 1201-1205

  Sun, Tie Ying ^a   Sun, Li ^b   Wang, Rong Mei ^c   Ren, Xiao Ping ^b   Sui, Dong Jiang ^c   Pu, Chun ^a   Ren, Ya Juan ^b   Liu, Ying ^c   Yang, Zhuo ^b   Li, Feng Zhi ^c  

^a BEIJING HOSPITAL   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Community acquired infection; Levofoxacin; Metronidazole; Moxifoxacin; Pneumonia

Indexed keywords

ANTIINFECTIVE AGENT; LEVOFLOXACIN PLUS METRONIDAZOLE; MOXIFLOXACIN; UNCLASSIFIED DRUG; LEVOFLOXACIN; METRONIDAZOLE; QUINOLONE DERIVATIVE;

ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; OPEN STUDY; PHLEBITIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; CLINICAL TRIAL; COMMUNITY-ACQUIRED INFECTIONS; MIDDLE AGED; PNEUMONIA;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; LEVOFLOXACIN; MALE; METRONIDAZOLE; MIDDLE AGED; PNEUMONIA; PROSPECTIVE STUDIES;

EID: 84897950719     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131635     Document Type: Article

References (13)

1. Sun TY. Value of Ertapenem on pneumonia in elderly patients (in Chinese). Chin J Pract Intern Med 2008; 28: 605-606.
2. Kikuchi R, Watabe N, Konno T, Mishina N, Sekizawa K, Sasaki H. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994; 150: 251-253.
3. Zheng H, Chen JN, Yu X, Jiang P, Yang WJ. Aspiration pneumonia of senile patients: analysis of clinical feature and etiology (in Chinese). Chin J Nosocomiol 2008; 18: 372-375.
4. Goldstein EJ, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez H. In vitro activity of moxifoxaxin against 923 anaerobes isolated from human intra abdominal infections. Antimicrob Agents Chemother 2006; 50: 148-155.
5. Chinese Medical Association of Respiratory Diseases. Diagnosis and treatment guidelines of Community-acquired pneumonia (in Chinese). Chin J Tuberc Respir Dis 2006; 29: 651-655.
6. Petroianni, Ceccarelli D, Conti V, Terzano C. Aspiration pneumonia pathophysiological aspects, prevention and management. Panminerva Med 2006; 48: 231-239.
7. Paintal HS, Kuschner WG. Aspiration syndromes: 10 clinical pearls every physician should know. Int J Clin Pract 2007; 61: 846-852.
8. Zhang CF, Zhang WY. The etiology, antibiotics applications and prognosis of different types of aspiration pneumonia in the elderly. J Clin Pulmonary Med 2012; 17: 1747-1751.
9. Liu YN, Chen MJ, Zhao TM, Wang H, Wang R, Liu QF, et al. A multicentre study on the pathogenic agents in 665 adult patients with community-acquired pneumonia in cities of China (in Chinese). Chin J Tuberc Respir Dis 2006; 29: 3-8.
10. Breilh D, Jougon J, Djabarouti S, Gordien JB, Xuereb F, Velly JF, et al. Diffusion of oral and intravenous 400mg once-daily moxifloxacin into lung tissue pharmacokinetic steady-state. Chemotherpy 2003; 15: 558-556.
11. Behra Miellet J, Dubreuil L, Jumas-Bilak E. Antianaerobie activity of moxifloxacin compared with that of ofloxaein, ciprofoxacin, clindamycin, metronidazole and beta.1aetams. Int J Antimicrob Agents 2002; 20: 366-374.
12. Ott SR, Allewelt M, Lorenz J, Reimnitz P, Lode H. Moxifoxacin vs. ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008; 36: 23-30.
13. Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, et al. Moxifloxacin monotherapy is effective in hospitalized patients with community acquired pneumoniae: the MOTICV study-A clinical trial. Clin Infect Dis 2008; 46: 1499-1509.